Systems and methods for visualizing future skin trends based on biomarker analysis

Patent metadata

Field	Value
Publication number	US-11127176-B2
Application number	US-201916264181-A
Country	US
Kind code	B2
Filing date	Jan 31, 2019
Priority date	Jan 31, 2019
Publication date	Sep 21, 2021
Grant date	Sep 21, 2021

Abstract

Systems, methods, and devices are provided for generating visualizations of facial aging trends based on protein biomarker concentration information. Protein biomarker concentration information is generated by an immunoassay analyzer device. The protein biomarker concentration information is used to predict one or more facial aging trends, such as shiny skin, rough skin, uneven skin tone, eye wrinkles, photo-aging, loss of elasticity, or dilated pores. A visualization, such as a spider diagram or a face aging simulation, is generated and presented.

First claim

The invention claimed is:

1. A method of generating a facial aging visualization of a subject, the method implemented by at least one computer processor programmed by one or more machine instructions, the method comprising:
determining a predicted future presence of at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from a sample collected from the subject;
generating a virtual representation on an electronic display indicative of the predicted future presence of the at least one clinical sign of aging in the absence of any treatment; and
generating at least one virtual representation on the electronic display indicative of a predicted effect of at least one treatment on the predicted future presence of the at least one clinical sign of aging;
wherein determining the predicted future presence of the at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from the sample collected from the subject includes determining the predicted future presence of the at least one clinical sign of aging based on receiving information about a concentration of or information indicative of a presence or absence of at least one of an FLG2 biomarker, a TG3 biomarker, an IDE biomarker, and a YKL40 biomarker.

2. The method of claim 1 , further comprising updating a life-time aging trend indicator based on receiving protein biomarker concentration information.

3. The method of claim 1 , further comprising receiving one or more inputs indicative of protein biomarker concentration information from an immunoassay analyzer device.

4. The method of claim 1 , wherein determining the predicted future presence of the at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from the sample collected from the subject includes determining the predicted future presence of at least one of shiny skin, rough skin, uneven skin tone, eye wrinkles, photo-aging, loss of elasticity, or dilated pores based on receiving the protein biomarker concentration information.

5. The method of claim 1 , wherein generating the virtual representation on an electronic display indicative of the predicted future presence of the at least one clinical sign of aging includes generating a spider diagram or a face aging simulation.

6. The method of claim 1 , wherein the method further comprises receiving one or more questionnaire responses, and wherein the determination of the predicted future presence of the at least one clinical sign of aging is further based on the one or more questionnaire responses.

7. A system for generating a facial aging visualization of a subject, the system comprising:
circuitry for determining a predicted future presence of at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from a sample collected from the subject; and
circuitry for generating a virtual representation on an electronic display indicative of the predicted future presence of the at least one clinical sign of aging, wherein the virtual representation includes a rate of change of the clinical sign of aging;
wherein the circuitry for determining the predicted future presence of the at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from the sample collected from the subject includes circuitry for determining the predicted future presence of the at least one clinical sign of aging based on receiving information about a concentration of or information indicative of a presence or absence of at least one of an FLG2 biomarker, a TG3 biomarker, an IDE biomarker, and a YKL40 biomarker.

8. The system of claim 7 , further comprising circuitry for updating a life-time aging trend indicator based on receiving protein biomarker concentration information.

9. The system of claim 7 , further comprising circuitry for receiving one or more inputs indicative of protein biomarker concentration information from an immunoassay analyzer device.

10. The system of claim 7 , wherein the circuitry for determining the predicted future presence of the at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from the sample collected from the subject includes circuitry for determining the predicted future presence of at least one of shiny skin, rough skin, uneven skin tone, eye wrinkles, photo-aging, loss of elasticity, or dilated pores based on receiving protein biomarker concentration information.

11. The system of claim 7 , wherein the circuitry for generating the virtual representation indicative of the predicted future presence of the at least one clinical sign of aging includes circuitry for generating a spider diagram or a face aging simulation.

12. The system of claim 7 , further comprising circuitry for receiving one or more questionnaire responses, wherein the circuitry for determining the predicted future presence of the at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from the sample collected from the subject is configured to further base the determination of the predicted future presence of the at least one clinical sign of aging on the one or more questionnaire responses.

13. A computing device configured to:
determine a predicted future presence of at least one clinical sign of aging for a subject based on receiving protein biomarker concentration information generated from a sample collected from the subject;
determine a first predicted effect of a first treatment regimen on the predicted future presence of the at least one clinical sign of aging:
determine a second predicted effect of a second treatment regimen on the predicted future presence of the at least one clinical sign of aging: and
generate a first virtual representation on an electronic display indicative of the first predicted effect of the first treatment regimen on the predicted future presence of the at least one clinical sign of aging: and
generate a second virtual representation on an electronic display indicative of the second predicted effect of the second treatment regimen on the predicted future presence of the at least one clinical sign of aging;
wherein determining the predicted future presence of the at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from the sample collected from the subject includes determining the predicted future presence of the at least one clinical sign of aging based on receiving information about a concentration of or information indicative of a presence or absence of at least one of an FLG2 biomarker, a TG3 biomarker, an IDE biomarker, and a YKL40 biomarker.

14. The computing device of claim 13 , further configured to update a life-time aging trend indicator based on receiving protein biomarker concentration information.

15. The computing device of claim 13 , further configured to receive one or more inputs indicative of protein biomarker concentration information from an immunoassay analyzer device.

16. The computing device of claim 13 , wherein determining the predicted future presence of the at least one clinical sign of aging for the subject based on receiving protein biomarker concentration information generated from the sample collected from the subject includes determining a predicted future presence of at least o

Assignees

• Oreal

Inventors

• Balooch Guive
• Messager Edouard
• Foucher Aude
• Cavusoglu Nukhet
• Lee Ji

Classifications

• G06T11/26 Primary

  Drawing of charts or graphs · CPC title

• G16H50/50

  for simulation or modelling of medical disorders · CPC title

• G16H50/20 Primary

  for computer-aided diagnosis, e.g. based on medical expert systems · CPC title

• G16H30/40

  for processing medical images, e.g. editing · CPC title

• G16H10/40

  for data related to laboratory analysis, e.g. patient specimen analysis · CPC title